Medical breakthrough: Scientists reprogramme immune cells via injection to fight cancer.

A US research team has reported a breakthrough in cancer medicine. Rather than painstakingly modifying immune cells in the laboratory, they have, for the first time, managed to reprogramme certain defence cells directly inside the body. Early results from animal studies look so powerful that specialists are already talking about a potential turning point in cancer treatment.

How CAR‑T therapy works today - and where it reaches its limits

CAR‑T cell therapy is already regarded as one of the most advanced weapons against blood cancer. Clinicians remove T cells - specialised immune cells - from a patient and, in the laboratory, equip them with an artificial receptor known as the “Chimeric Antigen Receptor”, or CAR.

This CAR acts like a highly sensitive antenna: it detects specific features on the surface of cancer cells. When the engineered T cells encounter those features, they attack the tumour and can selectively destroy cancer cells.

The US medicines regulator has already approved several CAR‑T therapies for certain types of leukaemia and lymphoma. Many people respond even after conventional chemotherapy or radiotherapy has failed.

Why so many people still cannot access CAR‑T

Despite striking successes, CAR‑T remains a niche option. The main reason is the complex manufacturing pathway:

• T cells are collected from the blood
• the cells are genetically altered in a specialist laboratory
• the modified cells are expanded over days to weeks
• the cells are returned to the patient via infusion

This requires time, highly trained staff, and infrastructure that costs millions. Many hospitals - especially smaller ones - are unable to offer such a treatment at all. On top of that, the price tag is extremely high, placing strain on health systems and making access harder for patients.

"Waiting times of several weeks and six‑figure costs make modern cancer immunotherapies unattainable for many people affected."

There is also a technical drawback: the conventional approach often uses viruses to insert new genetic material into cells. These viruses integrate the CAR gene at random points in the genome. The result is a mixed population of cells - some work exceptionally well, others hardly at all.

The new approach: in vivo engineering of CAR‑T cells with gene editing inside the body

This is precisely where the University of California, San Francisco team comes in. Working with several partner institutes, the researchers developed a system that can specifically modify T cells directly within the body. Experts refer to this as “in vivo engineering” - gene engineering in a living organism.

To achieve this, the team uses two different delivery vehicles. The first carries the CRISPR‑Cas9 tool into cells. CRISPR functions like molecular scissors, able to cut DNA at a precisely chosen location. The second vehicle delivers the new blueprint for the CAR receptor.

The crucial point is that the CAR gene is not inserted randomly. Instead, it is placed into a defined location in the T‑cell genome known as the TRAC locus. This segment normally controls the natural T‑cell receptor.

"By placing it in the TRAC locus, the CAR is initiated like a native programme - only in T cells, controlled and well dosed."

This solves several issues at once: the modified cells produce the CAR receptor in a much more uniform pattern, the risk of uncontrolled effects is reduced, and other cell types remain largely unaffected.

One injection, a strong effect: what the animal studies showed

The method was tested in mice with an immune system similar to that of humans. The animals received a single injection containing the gene delivery vehicles - and the outcome surprised even the researchers.

In models of aggressive leukaemia, tumours disappeared completely in a large share of the animals. In some experiments, the reprogrammed T cells made up as much as 40 per cent of all immune cells in the body after just one treatment.

More striking still, the approach did not only work for blood cancers such as leukaemia or multiple myeloma. It also showed effects in models of solid tumours. These compact tumours - for example, those in organs - have so far been considered particularly difficult for CAR‑T therapies to tackle.

Immune cells with memory

Another notable finding is that the newly programmed T cells appear to remember the cancer. In follow‑up experiments, researchers exposed the animals to tumour cells again after successful treatment.

The immune response was faster and stronger than the first time. The number of cancer‑hunting cells in the blood rose rapidly, and the tumours could be brought back under control. This kind of immunological memory is exactly what oncologists want in order to prevent relapses.

"In the studies, the CAR‑T cells generated directly in the body sometimes even appeared fitter than variants grown in the laboratory."

The researchers involved suspect that T cells that are never removed from the body preserve their “youthfulness” better. They divide more readily and remain more adaptable - two traits that matter for durable cancer control.

Greater safety through targeted control

For any such method to become a candidate for human use, safety is central. The California teams and their partners therefore refined the approach at multiple points:

• the delivery vehicles were designed to preferentially target T cells
• the likelihood of genetically altering other cell types is markedly reduced
• the vehicle coatings were engineered so the immune system breaks them down less quickly

In the animal studies conducted so far, there were no major immune misreactions. Of course, such findings cannot replace clinical trials in people, but they do provide important indications that the approach could be broadly tolerable.

Why this could reshape cancer treatment

If the results are confirmed in human studies, the implications for cancer medicine would be far‑reaching. Several of today’s bottlenecks in CAR‑T therapy could be significantly eased:

Challenge today	Potential benefit of the new method
Weeks‑long wait for laboratory manufacturing	Cells are modified directly in the body after the injection
High production costs and reliance on specialist labs	Standardised manufacturing of gene delivery vehicles, potentially cheaper
Therapy available only at a small number of centres	In principle usable in smaller hospitals too
Strongly variable quality of cell products	Targeted insertion into the genome, consistent CAR expression

In this context, oncologists talk about a possible “democratisation” of CAR‑T therapy: instead of being a high‑end intervention for a few, it could become a much more widely available option - ideally starting with a single injection.

How realistic is use in people?

As much excitement as the animal data generate, several hurdles remain before patients can truly benefit:

• clinical trials to assess safety in humans
• how mouse dosing translates to human dosing
• risk evaluation for long‑lasting genetic changes
• regulatory requirements from licensing authorities

Using CRISPR inside the body is particularly sensitive. Any unintended genetic change could have long‑term consequences. The precise targeting of the TRAC site reduces risk, but it cannot eliminate it entirely.

What terms like CAR, T cell and CRISPR actually mean

To better grasp the significance of the approach, it helps to clarify the key concepts:

• T cells: specialist units of the immune system that can recognise and destroy abnormal cells.
• CAR (Chimeric Antigen Receptor): an artificially engineered receptor on T cells that recognises specific surface structures on tumour cells.
• CRISPR‑Cas9: a tool that allows researchers to cut and rewrite DNA at predetermined locations.
• TRAC locus: a section of DNA in T cells that normally controls the natural T‑cell receptor - well suited for inserting new programmes such as CAR in a controlled manner.

What makes the new strategy so powerful is the combination of precise cutting, targeted insertion, and using a natural switch within the immune system.

Risks and opportunities patients should be aware of

For many people with hard‑to‑treat cancer, the study raises substantial hopes. Those treated in smaller hospitals - or those who currently must travel long distances - could benefit if the therapy can be standardised as an injection.

At the same time, risks remain: immune reactions, unintended genetic changes, and possible overactivation of the immune response (for instance, in the form of a cytokine storm) will all need close monitoring in upcoming studies. The cost question is also unresolved: a technically simpler process does not automatically mean the therapy will become inexpensive straight away.

The study, published in the journal Nature, makes one point very clearly: reprogramming immune cells directly inside the body is no longer a distant vision, but a concrete, working concept. How quickly it becomes an approved therapy now depends on the next years of research and regulation - and on whether the impressive mouse data can be reproduced in humans.